Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune ...

Thetis Pharmaceuticals, LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD) and cancer, today announced the appointment ...

Microbiotica has announced positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

Flerie AB's (publ) portfolio company Microbiotica has reported positive results from its Phase 1b first-in-human study of MB310 in patients with ulcerative colitis (UC). The positive data support Micr ...

(Alliance News) - IP Group PLC on Wednesday said portfolio company Microbiotica Ltd has announced positive results from a phase 1b first-in-human trail of MB310 in ulcerative colitis patients.

The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.

Young adults with IBD are more likely to face step therapy mandates, making clinicians concerned that insurers are ignoring evidence-based guidelines and imperiling outcomes.

A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, longer‑lasting, precision treatments.

SHANGHAI, Feb 11 (Reuters) - Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel ...

Microscopic fibers secretly shape how every organ in the body works, yet they’ve been notoriously hard to study—until now. A new imaging technique called ComSLI reveals hidden fiber orientations in ...

Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...